Brief: Algernon Pharmaceuticals To Conduct Phase 1 DMT Stroke Program Study With Hammersmith Medicines Research
01/03/2021 14:10
March 1 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON PHARMACEUTICALS TO CONDUCT PHASE 1 DMT STROKE
PROGRAM
STUDY WITH HAMMERSMITH MEDICINES RESEARCH (UK)
Source text for Eikon: ID:nGNX9WcfPD
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement